ADAS-Cog
Neurology· appears in 215+ cited findings in this library
What it is and how the reviews use it
The ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive Subscale) is a widely used endpoint in regulatory reviews for treatments targeting Alzheimer's disease. It measures cognitive function, with different versions having varying score ranges. The ADAS-Cog 13 has a score range from 0 to 85, as noted in the Eli Lilly and Company — Kisunla FDA Review (BLA761248, ORIG 1, 2024), while the ADAS-cog has a score range of 0 to 70 according to the SANDOZ — Exelon FDA Review (NDA/BLA 022083, 2016). The ADAS-Cog 14 scale has a range from 0 to 90, as seen in the EISAI INC — Leqembi FDA Review (NDA/BLA 761269, 2024).
Regulatory reviews in this library frequently use ADAS-Cog to assess treatment effects on cognitive decline. For instance, the Eli Lilly and Company — Kisunla FDA Review (BLA761248, ORIG 1, 2024) reported an ADAS-Cog 13 treatment effect of -1.33 [-20%]. In the SANDOZ — Exelon FDA Review (NDA/BLA 022083, 2016), the ADAS-cog treatment difference was -1.47. The EISAI INC — Leqembi FDA Review (NDA/BLA 761269, 2024) noted a change from baseline in ADAS-Cog14 of -2.31.
Real examples — cited to the source page
| COGNITION THERAPEUTICS INC | ADAS-Cog 11 slowing in lower p-tau217 population | 95 | SEC 8-K, p.23 |
| EISAI INC | Pearson correlation coefficient between amyloid PET and ADAS-Cog14 | 0.699 | Leqembi FDA Summary Review, p.27 |
| Eisai Co., Ltd. | ADAS-Cog14 change from baseline (PBO) | 5.907 | Leqembi EMA EPAR public assessment report, p.236 |
| Eli Lilly and Company | ADAS-Cog13 change from baseline (donanemab vs placebo) | -1.16 | Kisunla EMA EPAR public assessment report, p.67 |
| SANDOZ | ADAS-cog treatment difference | -1.47 | Exelon FDA Review, p.37 |
| Eli Lilly and Company | ADAS-Cog 13 treatment effect | -1.33 [-20%] | Kisunla FDA Review, p.11 |
| EISAI INC | Change from baseline in ADAS-Cog14 | -2.31 | Leqembi FDA Review, p.38 |
| Eisai Co., Ltd. | Pearson correlation coefficient between amyloid PET SUVR and ADAS-Cog14 | 0.699 | Leqembi FDA Review, p.282 |
Different drugs were studied in different trials — these values are not head-to-head comparisons.
Explore the full evidence
Every ADAS-Cog finding in the library — searchable and answerable in plain language — is in the Neurology research library →
Figures are as stated in the cited source documents. Educational reference only — not medical or investment advice.